Key Transaction Details

Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialization of two insulin analogues in India:

  • Insulin Degludec
  • Insulin Degludec + Aspart Combination

Strategic Rationale and Impact

The partnership represents a significant step in Mankind Pharma's strategy to strengthen its presence in diabetes care and broaden its portfolio of advanced injectable therapies. The addition of these products will enhance the company's position in the injectable diabetes segment, contributing to a more comprehensive portfolio and reinforcing its commitment to addressing the evolving needs of patients.

Executive Commentary

Atish Majumdar, Senior President – Sales and Marketing, Mankind Pharma Ltd., commented: "China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment."

Broader Strategic Context

The partnership aligns with Mankind Pharma's broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities. China's rapidly developing biopharmaceutical ecosystem presents opportunities for Indian pharmaceutical companies to access differentiated and innovative assets that can complement their existing portfolios.

Company Background Information

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, focusing on the domestic market with Pan India presence. The company operates at the intersection of pharmaceutical formulations and consumer healthcare sectors, with a strategy to provide quality products at affordable prices.

Distribution and Manufacturing Capabilities

Mankind's distribution network includes a robust field force of 18,500+ professionals, reaching over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, supported by 7 dedicated R&D facilities backed by more than 740 scientists.